drugset / Trial / NCT05759234
A Study of HS248 in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This study is a non-random, open multi-center study This study is a non-random, open multi-center phase I study, aimed at evaluation period research, aimed at In the evaluation phase study, it aims to evaluate the safety, tolerance PK characteristics and preliminary anti-tumor activity of HS248 in patients with advanced solid tumors. The study was divided into 2 phases, including dose escalation and dose expansion。
Timeline
- Start
- 2022-11-15
- Primary completion
- 2023-10
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS248 | Unknown | 20 mg | — |
| Subject | HS248 | Unknown | 40 mg | — |
| Subject | HS248 | Unknown | 60 mg | — |
| Subject | HS248 | Unknown | 80 mg | — |